MASHINIi

Silence Therapeutics Plc.

SLN.US | Research and experimental development on natural sciences and engineering

Silence Therapeutics Plc is a biotechnology company focused on the discovery and development of novel ribonucleic acid interference (RNAi) therapeutics. The company's primary focus is on developing medicines by harnessing the body's natural mechanisms to silence disease-causing genes. Silence Therap...Show More

Ethical Profile

Mixed.

Silence Therapeutics Plc receives a mixed ethical rating. The biotechnology company is fundamentally committed to improving health, developing innovative siRNA therapies for cardiovascular, hematological, and rare diseases with unmet medical needs. However, as a drug development firm, it inherently relies on animal testing during preclinical and clinical phases, which critics point to as a conflict with animal welfare values. While the company made charitable donations of £75,000 in both 2021 and 2022, there is insufficient public information to assess its performance across many other ethical areas, including fair pay, environmental impact, or ethical sourcing, resulting in neutral scores in these categories.

Value Scores

Better Health for All40
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-50
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech-10
-100100
Zero Waste & Sustainable Products-50
-100100

Better Health for All

40

Silence Therapeutics' core business is developing precision-engineered RNAi therapeutics to silence disease-causing genes, aiming to transform lives by addressing unmet medical needs. Their lead candidate, Zerlasiran (SLN360), demonstrated a median percentage reduction in Lipoprotein(a) (Lp(a)) of 90% or greater in a Phase 2 study (ALPACAR-360) at week 36.

1
High Lp(a) is a genetic risk factor for atherosclerotic cardiovascular disease (ASCVD), affecting up to 20% of the world's population, or approximately 1.4 billion people globally.
2
The company has no revenue from products with negative health impacts, as all offerings are investigational therapies designed for health improvement. No new safety concerns were identified during the 36-week treatment period of the ALPACAR-360 study.
3
The company focuses on patients with limited or inadequate treatment options and is developing SLN360 as a potential long-term preventative treatment.
4
Silence Therapeutics pioneers in siRNA design and development, utilizing its proprietary mRNAi GOLD™ platform, and maintains R&D collaborations with partners like AstraZeneca and Hansoh Pharma.
5
The company promises to treat data with respect and not share information with any third party.
6
Silence conducts clinical trials to the highest standards of safety and ethics, with more information available on clinicaltrials.gov.
7

Fair Money & Economic Opportunity

0

No evidence available to assess Silence Therapeutics Plc on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess Silence Therapeutics Plc on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No evidence available to assess Silence Therapeutics Plc on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No evidence available to assess Silence Therapeutics Plc on Honest & Fair Business.

Kind to Animals

-50

The company uses in silico algorithms and in vitro screening for early-stage identification of siRNAs, but top candidates are subsequently tested for safety and efficacy in animal models.

1
Non-human primate studies are required for drug candidate selection for clinical trials.
2
The company explicitly states it uses animals for product testing, and there is no evidence of a policy to reduce or phase out animal testing.
3

No War, No Weapons

0

Silence Therapeutics Plc is a biotechnology company focused on RNAi therapeutics. The provided articles consistently state that the company's activities are not applicable to the arms or defense industry, nor to peacebuilding or conflict-related sectors. Therefore, all KPIs related to arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investment, conflict divestment, defense oversight, export controls, lobbying on arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance, ethical red lines, controversial weapons exposure, war-risk audits, conflict partner reviews, defense divestment, conflict minerals, peace tech investment, and conflict zone procurement are marked as N/A, indicating no involvement in these areas.

1

Planet-Friendly Business

0

No evidence available to assess Silence Therapeutics Plc on Planet-Friendly Business.

Respect for Cultures & Communities

0

No specific, concrete data points were found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. The articles primarily focus on financial performance, clinical trials, and general corporate conduct, without detailing engagement with local or indigenous communities, cultural impact assessments, or specific charitable giving to cultural heritage organizations.

1

Safe & Smart Tech

-10

The company has no documented data breaches or incidents of unauthorized data use.

1
It acknowledges being subject to stringent and evolving data privacy and security laws and regulations, and states that failure to comply could lead to regulatory actions, fines, and penalties.
2
The company mentions a 'Privacy and Cookie Notice' and the ability for users to unsubscribe from investor alerts, indicating basic data control options.
3
However, there is no evidence of specific compliance programs, certifications, or regulatory penalties.
4

Zero Waste & Sustainable Products

-50

Silence Therapeutics has issued company recommendations to reduce individual employee’s environmental impact and promote better work-from-home practices.

1
The company's operations involve hazardous materials and waste, and it is subject to numerous environmental, health, and safety laws and regulations governing their handling, use, storage, treatment, and disposal.
2
The company and its contract manufacturers are also subject to periodic inspections by regulatory authorities to ensure compliance with cGMP.
3

Own Silence Therapeutics Plc?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.